BL Pharmtech Corp.

KOSDAQ:A065170 Stock Report

Market Cap: ₩20.8b

BL Pharmtech Past Earnings Performance

Past criteria checks 0/6

BL Pharmtech's earnings have been declining at an average annual rate of -1.5%, while the Personal Products industry saw earnings growing at 13.7% annually. Revenues have been declining at an average rate of 27.1% per year.

Key information

-1.5%

Earnings growth rate

3.8%

EPS growth rate

Personal Products Industry Growth3.8%
Revenue growth rate-27.1%
Return on equity-29.2%
Net Margin-65.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why BL Pharmtech (KOSDAQ:065170) Can Afford Some Debt

Dec 18
Here's Why BL Pharmtech (KOSDAQ:065170) Can Afford Some Debt

BL Pharmtech (KOSDAQ:065170) Has Debt But No Earnings; Should You Worry?

Sep 03
BL Pharmtech (KOSDAQ:065170) Has Debt But No Earnings; Should You Worry?

Some Confidence Is Lacking In BL Pharmtech Corp.'s (KOSDAQ:065170) P/S

May 21
Some Confidence Is Lacking In BL Pharmtech Corp.'s (KOSDAQ:065170) P/S

Is BL Pharmtech (KOSDAQ:065170) A Risky Investment?

Mar 07
Is BL Pharmtech (KOSDAQ:065170) A Risky Investment?

Reflecting on Next Bt's (KOSDAQ:065170) Share Price Returns Over The Last Three Years

Mar 14
Reflecting on Next Bt's (KOSDAQ:065170) Share Price Returns Over The Last Three Years

Does Next Bt (KOSDAQ:065170) Have A Healthy Balance Sheet?

Jan 20
Does Next Bt (KOSDAQ:065170) Have A Healthy Balance Sheet?

Next Bt's (KOSDAQ:065170) Shareholders Are Down 43% On Their Shares

Nov 28
Next Bt's (KOSDAQ:065170) Shareholders Are Down 43% On Their Shares

Revenue & Expenses Breakdown

How BL Pharmtech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A065170 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,943-7,87511,5280
30 Jun 2416,710-10,37715,1560
31 Mar 2420,638-15,66818,5600
31 Dec 2324,525-14,10120,1370
30 Sep 23-19,190-17,86217,3950
30 Jun 23-2,525-15,11117,0370
31 Mar 2310,225-14,00616,8680
31 Dec 2222,523-14,69017,1660
30 Sep 2286,983-12,23222,4190
30 Jun 2282,282-12,74123,7040
31 Mar 2283,757-20,52424,1620
31 Dec 2184,440-20,21124,1790
30 Sep 2182,378-26,47322,8980
30 Jun 2177,279-33,18221,9240
31 Mar 2169,925-20,87421,0810
31 Dec 2065,691-17,94721,9690
30 Sep 2055,847-13,48827,9870
30 Jun 2054,165-3,72027,9920
31 Mar 2053,804-9,55028,8240
31 Dec 1958,869-11,82030,1320
30 Sep 1969,732-3,64826,2880
30 Jun 1980,466-5,81830,2950
31 Mar 1989,0621,24532,5740
31 Dec 1887,6861,30231,8880
30 Sep 1884,840-1,92134,0860
30 Jun 1882,673-1,12031,2370
31 Mar 1877,494-2,45828,1410
31 Dec 1783,708-3,05626,5940
30 Sep 1779,549-2,71722,3650
30 Jun 1777,111-3,30721,6630
31 Mar 1783,728-5,31724,8070
31 Dec 1673,963-5,07624,7000
30 Sep 1670,910-8,43924,5270
30 Jun 1667,218-8,73824,3340
31 Mar 1658,819-6,25921,1680
31 Dec 1557,145-6,51420,9480
30 Sep 1556,025-1,88120,0980
30 Jun 1559,532-1,42623,1290
31 Mar 1562,883-1,30625,4940
31 Dec 1461,595-1,04325,6370
30 Sep 1460,724-1,38525,7500
30 Jun 1456,481-1,27522,1050
31 Mar 1452,124-1,20320,6660
31 Dec 1350,703-1,60819,3390

Quality Earnings: A065170 is currently unprofitable.

Growing Profit Margin: A065170 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A065170 is unprofitable, and losses have increased over the past 5 years at a rate of 1.5% per year.

Accelerating Growth: Unable to compare A065170's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A065170 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (62.4%).

Return on Equity

High ROE: A065170 has a negative Return on Equity (-29.25%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 22:37
End of Day Share Price 2024/12/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BL Pharmtech Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehyeong KimKB Securities Co., Ltd.